Adage Capital Discloses 6% Stake in KV Pharma (KV-A)
Tweet
Share
E-mail
Adage Capital Partners filed a 13G with the U.S. Securities and Exchange Commission after the close Monday showing ownership of 2,950,000 shares, or 6.08%, of KV Pharmaceuticals (NYSE: KV-A).
Looking at its 13F quarterly filing, Adage did not appear to have a stake in KV prior to this filing.
K-V Pharmaceutical Company, together with its subsidiaries, develops, manufactures, acquires, and markets branded and generic/non-branded prescription pharmaceutical products.
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $25.7 billion in securities at the end of the quarter ended December 31, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
Looking at its 13F quarterly filing, Adage did not appear to have a stake in KV prior to this filing.
K-V Pharmaceutical Company, together with its subsidiaries, develops, manufactures, acquires, and markets branded and generic/non-branded prescription pharmaceutical products.
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $25.7 billion in securities at the end of the quarter ended December 31, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Werewolf Therapeutics to merge with Ambros in $150M private placement
- Lowe's (LOW) PT Lowered to $275 at Guggenheim
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
Create E-mail Alert Related Categories
13Gs, Hedge FundsRelated Entities
Adage Capital Management, Standard & Poor's, Hedge Funds, 13GSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
